Integrated needle-free injection and sensing using opto-microfluidics

Project Information

iSENS

Grant agreement ID: 101158591

DOI

10.3030/101158591

EC signature date 11 April 2024

Start date 1 July 2024

End date 30 June 2027

Funded under

• The European Innovation Council (EIC)

Total cost

€ 2 512 500,00

EU contribution

€ 2 499 999,00

Coordinated by

FLOWBEAMS BV
Netherlands

Periodic Reporting for period 1 - iSENS (Integrated needle-free injection and sensing using opto-microfluidics)

Reporting period: 2024-07-01 to 2025-06-30

Summary of the context and overall objectives of the project

Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level. Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments, while millions of used needles contaminate the environment every day. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet. Through the technological breakthrough we present in this project safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Started different experimental work in our new lab facility. We have hired additional engineers to strengthen the technical team. Together with them we have been working on further development of the jetting and injection technology and related aspects. Furthermore, validation studies have been performed using our prototype device. On a regulatory and business perspective, we have improved our strategy and roadmap towards first market access. Most of the preliminary results are confidential and will be disclosed at a later stage.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

We set up a new office and lab facility for the FlowBeams team to work on the further development of the technology. The development of the injection technology has been speeded up. Collaboration with the University of Twente has led to two scientific manuscripts which are currently in preparation for publication.
From a business perspective, we gained more traction in the cosmetic industry, also emphasized by the CES Innovation Award 2025 in Beauty & Personal Care category.
As the project is still running, most of the preliminary results are confidential and will be disclosed at a later stage.

FlowBeams: Pioneering precise needle-free injection for a healthier world